Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma

Clinical trial NCT06047197 · RECRUITING

Trial details

NCT number: NCT06047197
Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-cell Lymphoma

Start date: 2023-09-05
Primary completion: 2026-09-05
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.